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of quality of life with VCF patients after balloon kyphoplasty (BKP) was conﬁrmed 
in a randomised controlled trial (Fracture REduction Evaluation (FREE) trial). Objec-
tive of this study was to examine a cost-effectiveness of BKP in comparison with con-
servative medical management (CMM) for VCF in patients with osteoporosis in Japan. 
METHODS: A disease event simulation model was used to estimate a lifetime cost-
effectiveness of BKP compared to CMM for female VCF patients (70-year-old) with 
osteoporosis in Japan. Payer’s perspective was employed and only medical costs were 
estimated. BKP material price was set at JPY500,000 (a3650, a1  JPY137). Utilities 
were obtained from the FREE trial. Costs and quality-adjusted life years (QALYs) 
occurring beyond 1 year were discounted at 3% per year. Cost-effectiveness was 
evaluated by ICER (Incremental Cost Effectiveness Ratio). RESULTS: BKP was associ-
ated with increased QALYs (0.308 QALYs) compared to CMM. The incremental 
cost-effectiveness ratio for BKP compared to CMM was JPY1,399,947 (a10,219) per 
QALY gained. Probabilistic sensitivity analysis indicated a 76% likelihood that BKP 
would be considered cost-effective in Japan with a willingness to pay of up to JPY 
6 million (a43,796) per QALY gained. CONCLUSIONS: Compared to CMM, BKP 
for Japanese VCF patients was projected to improve QALYs and regarded as 
cost-effective.
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OBJECTIVES: To evaluate the cost-utility of different treatment strategies in the 
treatment of severe RA after the treatment failure with ﬁrst anti-TNF therapy (FATT). 
Before the treatment failure with FATT, patients are assumed to be treated with the 
FIN-RACo combination (methotrexate, sulfasalazine, hydroxychloroquine, and pred-
nisolone). METHODS: The cost-effectiveness of treatment strategies is compared in 
a group of hypothetical Finnish RA patients. After the treatment failure with FATT, 
the patients receive either best supportive care (BSC: intramuscular gold followed by 
cyclosporine and methotrexate) or one of the following treatments before BSC: ritux-
imab, etanercept, adalimumab or inﬂiximab. Further treatments are added to the most 
cost-effective strategy in a stepwise manner. The analysis is performed on an Excel-
based Markov state transition model using the probabilistic approach. The clinical 
outcomes related to treatments are estimated from published clinical trials using 
adjusted indirect comparison. The quality adjusted life-years (QALY) gained are esti-
mated on the basis of Health Utilities Index (HUI-3) and disease severity scores (HAQ). 
The resource use and costs are obtained from the Finnish treatment practice, a pub-
lished study of hospitalisations in RA, Finnish Unit Cost list and Finnish Medicine 
Tariff. RESULTS: The treatment with rituximab dominates adalimumab and etaner-
cept after the failure of FATT as it is more effective and less costly. A QALY gained 
with rituximab or inﬂiximab costs a32,083 or a38,490 compared to BSC, respectively. 
The ICERs are a53,606; a54,722 and a37,169 per QALY gained for adding adalim-
umab, etanercept and inﬂiximab to the rituximab strategy, respectively. According 
to the cost-effectiveness acceptability frontier only the treatments with rituximab or 
rituximab followed by inﬂiximab should be considered after the failure of FATT, if 
a50,000 per QALY gained is used as a willingness-to-pay threshold. CONCLUSIONS: 
Treatment with rituximab is a cost-effective 2nd line biologic treatment strategy in 
RA patients in Finland.
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OBJECTIVES: Poor compliance and failure to persist with osteoporosis medications 
are common, but the clinical and economic consequences have not been well 
described. This study aims to estimate the clinical and economic burden of nonadher-
ence with oral bisphosphonates in osteoporotic patients and to examine the scope for 
adherence-enhancing interventions. METHODS: A validated Markov microsimula-
tion model estimated costs and outcomes (i.e. the number of fractures and the 
quality-adjusted life-year (QALY)) for three adherence scenarios: no treatment, real-
world adherence and full adherence over three years. Simulated patients matched the 
populations where osteoporosis medications are reimbursed. The real-world adher-
ence scenario employed adherence data from a published Belgian observational study 
and adherence was divided into persistence and compliance. The incremental cost per 
QALY gained was estimated comparing the three adherence scenarios. We also 
examined the clinical and economic implications of adherence-enhancing interven-
tions assuming that adherence failure would be reduced by 10%, 20% or 30%. 
RESULTS: The estimated number of fractures prevented and the lifetime QALY 
gained in the real-world adherence scenario represents only 42.0% and 41.9% to 
that obtained under full adherence scenario, respectively. The cost per QALY gained 
of real-world adherence versus no treatment was estimated at a11,175, and full 
adherence was found to be cost-saving compared to real-world adherence. An inter-
vention that decreases adherence failure by 20% was associated with a 28% increase 
in the number of fractures prevented and the costs per QALY gained compared to 
real-world adherence were respectively a29,350 and a46,275 if the intervention costs 
a100 and a150 per year. CONCLUSIONS: This study suggests that more than half 
of the potential beneﬁts from oral bisphosphonates in patients with osteoporosis are 
lost due to poor compliance and failure to persist. Depending on its cost, interven-
tions that improve adherence to therapy have the potential to be an attractive use of 
resources.
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OBJECTIVES: Because little is known about the cost effectiveness of exercise therapy, 
general practitioners lack the knowledge to apply the most cost effective treatment to 
patients with the patellofemoral pain syndrome (PFPS). Therefore, we aimed to deter-
mine the cost effectiveness of exercise therapy (intervention group) compared to ‘usual 
care’ (control group) in adolescents and young adults dealing with PFPS in primary 
care. METHODS: This multicenter prospective cost-utility analysis was conducted at 
38 general practices and 3 sport medical advice centers in The Netherlands for 2007. 
A total of 131 patients between 14 and 40 years of age presenting with symptoms of 
PFPS and no history of previous active treatment were recruited. Direct medical and 
productivity costs were included for the follow up duration of one year. RESULTS: 
The annual direct medical costs per patient were signiﬁcantly higher for the interven-
tion group (a434) compared to the control group (a299), mainly caused by additional 
physiotherapy visits. Productivity costs amounted to a577 (SD2384) and a867 
(SD2192) for the two groups respectively, resulting in annual societal costs per patient 
which were signiﬁcantly lower in the intervention group (a 1,011 versus a1.166). 
Productivity costs due to reduced efﬁciency at paid work were responsible for 47% 
of the total costs in the intervention and 56% and in the control group. Patients in 
the intervention group experienced a slightly, but not signiﬁcantly, higher quality of 
life (0.8722 versus 0.8617). CONCLUSIONS: When only direct medical costs were 
included, average costs per quality adjusted life year (QALY) were a12,754. However, 
with a societal average cost effectiveness ratio of –a14,738 per QALY, exercise therapy 
appears to be cost effective as compared to ‘usual care’. The intervention was domi-
nant in 52% of the cases (positive health effects and cost savings) and inferior in 
14%.
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OBJECTIVES: Herniated discs (HDs) and depression place a signiﬁcant burden on 
employers. Although less prevalent, fractures may also have associated burden. The 
objective of this study was to evaluate the burden of fractures compared to HD and 
depression in terms of short-term disability (STD). METHODS: A descriptive retro-
spective analysis was conducted to assess STD associated with fractures (hip, non-
vertebral composite, vertebral). Medstat/MarketScan’s Health and Productivity 
Management data from 2003–2007 were used. All patients were 45–64 year-old 
employees, stratiﬁed by gender. Fracture-related STD was deﬁned as STD absence 7 
days prior to 14 days after the date of ﬁrst diagnosis of fracture. Cases were matched 
with a control with HD and a control with depression by age, gender, occupation, 
region, insurance type, and years of STD eligibility. RESULTS: HD and depression 
incidence was 30 and 55 per 1000 patient-years, respectively. Fracture incidence 
ranged from 0.6 cases for hip to 7 cases for nonvertebral fractures per 1,000 patient-
years. However, a higher proportion of fracture patients had an STD absence com-
pared to HD and depression controls. The proportion of events with an STD absence 
in women was 16.4% vs. 5.1%, 16.5% vs. 3.5%, and 11.8% vs. 5.4% for hip, non-
vertebral, and vertebral fractures vs. depression, respectively. For men, the rates were 
30.6% vs. 5.1%, 23.6% vs. 5.9%, and 23.7% vs. 6.7%. Comparison to HD controls 
yielded similar results. All p-values were 0.01. Among fracture patients, the mean 
days of STD absence (MDA) ranged from 93 (nonvertebral) to 148 (hip). The MDA 
was signiﬁcantly higher (p  0.05) in women for vertebral (vs. HD controls) and in 
men for hip (vs. both controls), vertebral (vs. depression controls), and non-vertebral 
fractures (vs. depression controls). CONCLUSIONS: Although fracture incidence is 
lower than HDs or depression, fractures produce signiﬁcantly higher STD burden per 
event in 45–64 year-old employees.
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OBJECTIVES: To determine indirect costs of RA and investigate factors potentially 
associated with higher indirect costs. METHODS: A mail survey was carried out 
among working age Rheumatoid Arthritis (RA) patients members of one RA patients’ 
association in France. Information on demographics, disease parameters, past and 
on-going treatments and employment status was collected. In addition, two validated 
instruments, Health Assessment Questionnaire (HAQ) and the EuroQoL-5 Dimension 
were considered. Annual indirect costs including sick leaves and RA-early retirement 
were valued from the French Health Insurance perspective. Two multiple logistic 
regression models were run to explain respectively the probability of having positive 
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indirect costs (versus 0) and the probability that patients with positive costs spent 
more than a4000 (versus less than a4000). RESULTS: Out of the 3494 questionnaires 
mailed 1189 (34.0%) were returned and fully completed. The mean age of respondents 
was 53.1 years (SD 8.6); 85.4% were women and the mean RA duration was 14.7 
years (SD 9.7). At the time of the survey, 49.9% of respondents were employed, 32.7% 
declared being on RA work disability perceiving pension invalidity. A total of 45.3% 
of employed patients had at least one sick leave over the past 6 months, with on 
average a cumulative duration of 11.6 days over. The average annual estimated indi-
rect cost was a3210 (74.4% RA-related work disability and 25.6% due to RA sick 
leaves). The three main risk factors associated with higher costs were: failure of at 
least one biotherapy (Odds Ratio-OR  4.8), RA poor functional status (severe HAQ 
versus mild HAQ, OR  3.8) and on-going treatment (disease-modifying antirheumatic 
drugs versus etanercept, OR  3.5). A high level of education is protective (OR  0.6). 
CONCLUSIONS: Pursuing preservation of functional status by treating patients 
earlier before irreversible joint damages could both improve patients’ work conditions 
and lead to potential savings for the Health Insurance.
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OBJECTIVES: Rituximab and inﬂiximab are biologic disease modifying anti-
 rheumatic drugs (DMARDS) used to treat rheumatoid arthritis (RA). Rituximab is 
re-dosed when signs and symptoms return, but inﬂiximab has ﬁxed dosing intervals. 
This 3-centre observational study was to determine the secondary care resource and 
patient time implications of this difference. METHODS: Medical records of 44 
patients with RA, treated with inﬂiximab (n  26) or at least 2 courses of rituximab 
(n  18) were reviewed retrospectively to determine mean time between end of 1st 
rituximab course and start of the 2nd, and numbers of visits and investigations for 
both drugs. Staff and patient time required for drug administration was measured 
prospectively by direct observation of 25 patients receiving inﬂiximab (n  13) or 
rituximab (n  12). RESULTS: Mean time between 1st and 2nd courses of rituximab 
was 43 weeks (range 15–84). During this time a mean of 6.9 (range 4–8) inﬂiximab 
infusions was administered. Rituximab-treated patients required 2 visits for drug 
administration during this time, vs. inﬂiximab 6.9 visits. Each visit required a mean 
of 87.2 minutes of staff time for rituximab patients vs. 46.0 minutes for inﬂiximab. 
Total staff time per patient over 43 weeks was 2.9 hours for rituximab vs. 5.3 hours 
for inﬂiximab. Mean total patient time in the unit per 43 weeks was 14.1 hours for 
rituximab vs. 25.3 hours for inﬂiximab. CONCLUSIONS: Although rituximab 
requires almost twice as much staff time per visit for its administration as inﬂiximab, 
it is administered less often so staff time required over a whole course is less for 
rituximab than inﬂiximab. An even greater difference was seen for patient time spent 
on the unit for drug administration. This study demonstrates beneﬁts from rituximab 
in terms of patient convenience and staff efﬁciency, which can inform NHS planning 
of service delivery and quality standards for patients with RA.
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OBJECTIVES: Anaemia is prevalent among old individuals. Iron deﬁciency due to 
chronic gastrointestinal loss is a frequent cause. Non-steroidal anti-inﬂammatory 
drugs (NSAIDs) are a major cause of bleeding among osteoarthritis (OA) patients. 
Analysis of Hospital Events Meaning IAtrogenicity (ANHEMIA) study aims at assess-
ing the demographic characteristics of anaemia in french OA patients and its impact 
on hospital length of stay (LOS). METHODS: Programme de Médicalisation des Sys-
tèmes d’Information (PMSI) database covers french hospital activity and is used by 
Health Authorities as resources use indicators for allocating and forecasting medical 
budget. Its Use to assess the epidemiological and economic burden of illness is recom-
mended. Cross-linkage through the ICD-10 diagnosis codes allowed the identiﬁcation 
of hospital stays with a main diagnosis of osteoarthritis (OA) and Among these, 
2 subpopulations according to the existence or absence of iron-deﬁciency anaemia 
(AN or AN-). ICD-10 diagnosis cancers were excluded. Four groups were established 
for analysis: OAAN-, OAAN in either private or public hospitals (PrH, PuH). 
RESULTS: All the groups analysis showed a higher percentage of women (p  0.001): 
2 out of every 3 patients. In PuH, mean age of OAAN patients was 73.5 years vs. 
65.3 for OAAN- patients, in PrH: 69.0 years (OAAN) vs. 58.3 (OAAN-). 
Overall, OAAN patients were signiﬁcantly older than 65 compared to OAAN- 
patients: 88.1% vs. 68.7% (p  0.001) both in PrH or PuH. Compared to OAAN- 
patients, OAAN patients had a longer LOS: 2.58 days in PuH, 2.49 days in PrH 
for matched DRG. The increase in LOS was accountable for substantial extra costs: 
a791,504 for PuH and a760,080 for PrH for the year 2006. CONCLUSIONS: 
Anaemia, is an important driver for extra-costs in hospitalized OA population. Since 
this population is likely to grow in the forthcoming years, every effort to reduce its 
incidence of anaemia should be considered.
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OBJECTIVES: Minimal Access Spinal Technologies (MAST TM) potentially allows 
surgeons to treat back pain and disability with the least amount of interruption while 
achieving the same surgical objectives as open surgeries. This single center resource 
use utilization study was designed to assess difference between MAST TM and open 
surgery in hospital length of stay and its associated costs from a hospital perspective. 
METHODS: This study aims at comparing the average length of hospital stay (LOS) 
of patients treated with MAST TM in the Foch hospital and the average National 
LOS of patients treated with open surgery. All patient operated with MASTTM in 
2007 in Foch hospital were retrospectively analyzed and were indirectly compared 
with patients from the National French DRG data base called PMSI. MASTTM and 
open surgery patients were matched on procedure code. Cost per hospital stay has 
been assessed with the French National Cost Study (ENC). RESULTS: In 2007, Foch 
hospital performed 250 MAST surgeries. The two main procedures were posterior 
lumbar arthrodesis (procedure code LFDA004/0; n  68) and removal of herniated 
disc (procedure code LFFA002/0; n  111). For posterior lumbar arthrodesis surgery, 
the average LOS in Foch Hospital was 5.9 days compared to 8.9 days in the national 
data base (34% decrease). For herniated disc surgery, the average LOS in Foch hospital 
was 3.4 days compared to 5.3 days in the national data base (36% decrease). In 2007, 
Foch hospital avoided 215 days of hospitalization with the MAST, representing 
between a133,000 and a141,000 (a320–a340 per day). CONCLUSIONS: By lowering 
morbidity and reducing recovery time, MAST TM reduces costs of hospital stays. The 
reduction of hospital days may off-set any additional device costs. Further prospective 
research should be considered to validate our ﬁndings; however this is one of the ﬁrst 
studies investigating systematically this subject.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcome Studies
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OBJECTIVES: To estimate the inﬂuence of non-compliance on the risk of fractures 
in German osteoporosis patients treated with oral bisphosphonate (oBP) therapy. 
METHODS: IMS® Disease Analyzer database was used; includes 11 million patients 
from ofﬁce-based physicians. Eligible osteoporosis patients (excluding malignant dis-
eases, any anticancer or cytostatic hormone prescription, Paget’s disease or AIDS) had 
data available q1-year before and after initiating oBP treatment (December 2004-
November 2007). Compliance was measured as Medical Possession Ratio (MPR; 
prescribed to assumed number of therapy units). MPR  80% assumed compliance. 
MPR was calculated for patients on therapy up to 2 years. Fractures were identiﬁed 
by ICD-10 codes; only fractures 3 months after initiating oBP were included. The 
inﬂuence of compliance on time to fracture was determined by Kaplan-Meier and Cox 
regression analyses. The model was adjusted for gender, age, prevalence of fractures 
1 year before index prescription, calcium/vitamin D co-prescription, continuation of 
the initial regimen after 6 months and after 1 year. RESULTS: A total of 4738 patients’ 
data were analyzed: 1365 (28.8%) with previous fractures. The total number of 
patients receiving oBP treatment was 177 (3.7%) daily, 4367 (92.2%) weekly and 
194 (4.1%) monthly. After 2 years, 14.5% (daily), 12.2% (weekly), and 9.7% 
(monthly) of patients experienced a fracture. The time to fracture was signiﬁcantly 
longer for compliant versus non-compliant patients (log rank test; p  0.013). Compli-
ance was associated with a 26% (95% CI 10–39%) decrease in the fracture rate versus 
non-compliance. Higher age (60 years) (44% increase; 95%CI 3–100%) and previ-
ous fractures (29% increase; 95%CI 5–57%) were associated with a signiﬁcantly 
higher risk of fractures. CONCLUSIONS: Patients receiving oBP therapy who are 
compliant have a decreased risk of fractures versus non-compliant patients. Older 
patients and those with fracture history are particularly at risk of fracture. These 
ﬁndings highlight the need to improve compliance to reduce the risk of osteoporosis-
associated fractures.
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OBJECTIVES: To examine the effect of medication choice between duloxetine and 
pregabalin on medication compliance outcomes as well as direct health care costs 
among patients with ﬁbromyalgia. METHODS: A retrospective cohort study design 
was used with a large US national commercial health care claims database over 
2005–2007. Fibromyalgia patients aged 18–64 who initiated (no pill coverage in the 
previous 90 days) duloxetine or pregabalin in 2006 were selected, with the ﬁrst initia-
tion date as the index date. All patients included had continuous enrollment in the 12 
